Complication following treatment with a microneedling technique for a female pattern hair loss: hair dye-induced tattoo-like pigmentation

Read full text
Authors: Anne Kelly Leroy, Daniel Fernandes Melo, Flavia Oliveira Xavier Brito, Rita Fernanda Cortez de Almeida
Cited by: 0

Abstract

Microinfusion of drugs into the skin (MMP ® ) is a Brazilian microneedling technique that employs professional tattoo devices for the delivery of pharmacological agents in conditions such as female pattern hair loss.We report an unexpected complication in a 44-year-old female patient who underwent hair dyeing 2 days after the procedure and subsequently developed linear pigmentation on the scalp resembling a tattoo.Trichoscopy revealed pigment deposition at the needle entry points, likely resulting from penetration of the hair dye.Although adverse effects of MMP ® are generally mild, this case highlights the importance of counseling patients regarding the use of hair dye following the procedure.Keywords: Androgenetic alopecia.Microinfusion of drugs into the skin ® .Female pattern hair loss. ResumoMMP ® (microinfusão de medicamentos na pele) é uma técnica brasileira de microagulhamento que utiliza equipamentos de tatuagem profissional para administração de fármacos em condições como a Alopecia de padrão feminino (FPHL).Relatamos complicação inesperada em paciente feminina de 44 anos que realizou tintura capilar dois dias após o procedimento, evoluindo com pigmentação linear semelhante a tatuagem no couro cabeludo.A tricoscopia evidenciou depósito pigmentário nos pontos de entrada das agulhas, provavelmente decorrente da penetração da tintura.Embora os efeitos adversos do MMP ® sejam, em geral, leves, este caso reforça a necessidade de orientar pacientes quanto ao uso da tintura pós-procedimento.

Fields of Study & Subjects

Hair Growth and Disorders Dermatologic Treatments and Research Tattoo and Body Piercing Complications

Publication details

Journal / source
Portuguese Journal of Dermatology and Venereology
Volume
84
Issue
2
Publication date
3 March 2026
Language
EN